Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Expert Panel Affirms ‘Continued Marketing’ Of Ambrisentan, Everolimus In India

Sanofi Ends Dronedarone Sales Due To Low Commercial Interest

Executive Summary

Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.

You may also be interested in...

India releases list of drugs approved without local trials

Faced with a barrage of questions and allegations of regulatory lapses in approving drugs for launch in the country, India's drugs regulator appears to have launched a transparency drive, putting out a host of approval details in public domain that includes a list of drugs recommended for approval without trials in the country.

Lilly, Sanofi, Novartis, Bayer deny wrongdoing, claim Indian report 'inaccurate'

Days after an Indian parliamentary committee report alleged a series of serious regulatory lapses in approving drugs for launch in the country, half a dozen leading companies named in the report including Lilly, Sanofi, Novartis, Bayer and Cipla claim that they have not flouted Indian laws and deny any wrongdoing.

Indian regulator in cahoots with industry and has 'skewed' priorities, says parliament

In what's perhaps one of the most damning reports on industry and the regulatory mechanism in India in recent times, a parliamentary standing committee on health and family welfare has charged that more than 30 new drugs were approved in the country without undergoing clinical trials.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts